NanoDimension adding European focus for new $335M fund

With third fund, NanoDimension planning its first-ever European investments while doubling down on therapeutics

NanoDimension intends to make its first-ever investments in Europe from its new $335 million third fund, with far more global emphasis on drug development than its previous funds have had.

The California-based firm has established an office in Lausanne, Switzerland, from which two partners will manage investments. European and American LPs, including family offices

Read the full 539 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE